A5009195100- Lymphoma Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Chronic Lymphocytic Leukemia Research
- Viral-associated cancers and disorders
- CNS Lymphoma Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- CAR-T cell therapy research
- Multiple and Secondary Primary Cancers
- Radiopharmaceutical Chemistry and Applications
- Genetic factors in colorectal cancer
- Medical Imaging Techniques and Applications
- Chronic Myeloid Leukemia Treatments
- Advanced Radiotherapy Techniques
- Lung Cancer Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Chemotherapy-induced cardiotoxicity and mitigation
- Esophageal Cancer Research and Treatment
Linköping University Hospital
2016-2025
Uppsala University
2019-2023
Linköping University
2020-2021
Vrinnevisjukhuset i Norrköping
2008
Balancing disease control and toxicity from chemotherapy radiotherapy (RT) when treating early-stage classical Hodgkin lymphoma (cHL) is important. Available data on long-term after RT for cHL mostly refer to techniques no longer in use. We aimed describe modern limited-field (LF)-RT two or four cycles of doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD).This study included all patients with treated ABVD 30 Gy LF-RT during 1999-2005 Sweden. Patients (n = 215) comparators 860), matched...
Summary When treating limited stage classical Hodgkin lymphoma (cHL), balancing treatment efficacy and toxicity is important. Toxicities after extended‐field radiotherapy are well documented. Investigators have aimed at reducing without compromising efficacy, mainly by using combined modality (CMT), i.e. chemotherapy limited‐field radiotherapy. In some clinical trials, has been omitted. We evaluated 364 patients with I‐IIA cHL treated between 1999 2005. Patients were two or four cycles of...
Summary Non‐endemic Burkitt lymphoma (BL) is a rare germinal centre B‐cell‐derived malignancy with the genetic hallmark of MYC gene translocation and rapid tumour growth as distinct clinical feature. To investigate treatment outcomes, loss lifetime relapse risk in adult BL patients treated intensive immunochemotherapy, retrospective clinic‐based population‐based registries from six countries were used to identify 264 real‐world patients. The median age was 47 years majority had...
This study estimated the risk of second primary malignancies after Hodgkin's lymphoma (HL) in relation to family history cancer, age at diagnosis and latency, among 6946 patients treated for HL Sweden 1965-1995 identified through Swedish Cancer Register (SCR). First-degree relatives (FDRs) their were then ascertained together with Multi-Generation Registry SCR. The patient cohort was stratified on number FDRs standardised incidence ratios (SIRs) developing SM analysed. In cohort, 781...
Abstract Treatment for patients > 60 years with classical Hodgkin lymphoma (cHL) is problematic; there no gold standard, and outcome poor. Using the Swedish Lymphoma Registry, we analysed all diagnosed cHL between 2000 2014 ( N = 2345; median age 42 years; 691 were >60 years). The follow‐up time was 6.7 years. elderly consisted mainly of ABVD or CHOP, younger treated BEACOPP (with survival difference). In multivariable analysis years, correlated better than CHOP p 0.027), became more...
Introduction: Lutetium (177Lu) lilotomab satetraxetan (Betalutin®) is a novel beta-emitting anti-CD37 ARC in ready-to-use formulation. CD37 highly expressed (>90%) B-cell NHL, providing an alternative target to CD20. LYMRIT 37-01 phase I/II, open-label, dose-escalation study evaluate the safety and preliminary efficacy of Betalutin® monotherapy patients (pts) with relapsed non-Hodgkin's lymphoma (NHL). We present updated data for all pts as February 13, 2017. Methods: Pts histologically...
The optimal management of the small number patients who experience early failure eBEACOPP in Hodgkin lymphoma (HL) is unclear. We identified 12 with HL progressed within months front-line therapy between January 2010 and July 2019. Median time first progression following diagnosis was 7 (range 2.1–13.2). Nine proceeded to stem cell salvage (8 autografts, 1 allograft). Seven received novel after relapse, these, 6 were alive at census, versus 2 out 5 those had standard alone. At end follow up...
Introduction: Classical Hodgkin lymphoma (cHL) often occurs in early adulthood and disease control is achieved by several treatment strategies, including radiotherapy (RT) added to chemotherapy stage disease. Long-term treatment-related toxicity therefore an important issue, particular with regard from RT. Even if the latter seems be reduced as methods of delivery are being refined, repeated investigations long-term results warranted. Methods: A Swedish population-based cohort, n = 215,...